Hong Shen

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/8227452/publications.pdf

Version: 2024-02-01

43 papers	1,388 citations	331538 21 h-index	345118 36 g-index
43 all docs	43 docs citations	43 times ranked	747 citing authors

#	Article	IF	Citations
1	Prediction of drugâ€“drug interaction potential mediated by transporters between dasatinib and metformin, pravastatin, and rosuvastatin using physiologically based pharmacokinetic modeling. Cancer Chemotherapy and Pharmacology, 2022, 89, 383-392.	1.1	5
2	Recent advances in the translation of drug metabolism and pharmacokinetics science for drug discovery and development. Acta Pharmaceutica Sinica B, 2022, 12, 2751-2777.	5.7	27
3	Simultaneous measurement of mouse and human albumin in chimeric mice with humanized livers. Bioanalysis, 2022, 14, 267-278.	0.6	0
4	Cynomolgus Monkey as an Emerging Animal Model to Study Drug Transporters: In Vitro, In Vivo, In Vitro-to-In Vivo Translation. Drug Metabolism and Disposition, 2022, 50, 299-319.	1.7	14
5	Transporters in Drug Development: International Transporter Consortium Update on Emerging Transporters of Clinical Importance. Clinical Pharmacology and Therapeutics, 2022, 112, 485-500.	2.3	27
6	Transporter Activity Changes in Nonalcoholic Steatohepatitis: Assessment with Plasma Coproporphyrin I and III. Journal of Pharmacology and Experimental Therapeutics, 2021, 376, 29-39.	1.3	10
7	PBPK Model of Coproporphyrin I: Evaluation of the Impact of SLCO1B1 Genotype, Ethnicity, and Sex on its Interâ€Individual Variability. CPT: Pharmacometrics and Systems Pharmacology, 2021, 10, 137-147.	1.3	21
8	Endogenous Coproporphyrin I and III are Altered in Multidrug Resistance-Associated Protein 2-Deficient (TRâ^') Rats. Journal of Pharmaceutical Sciences, 2021, 110, 404-411.	1.6	7
9	Endogenous Plasma Kynurenic Acid in Human: A Newly Discovered Biomarker for Drug-Drug Interactions Involving Organic Anion Transporter 1 and 3 Inhibition. Drug Metabolism and Disposition, 2021, 49, 1063-1069.	1.7	8
10	Induction of Human Intestinal and Hepatic Organic Anion Transporting Polypeptides: Where Is the Evidence for Its Relevance in Drug-Drug Interactions?. Drug Metabolism and Disposition, 2020, 48, 205-216.	1.7	36
11	Detection of Weak Organic Anionâ€“Transporting Polypeptide 1B Inhibition by Probenecid with Plasma-Based Coproporphyrin in Humans. Drug Metabolism and Disposition, 2020, 48, 841-848.	1.7	21
12	Absence of OATP1B (Organic Anionâ€“Transporting Polypeptide) Induction by Rifampin in Cynomolgus Monkeys: Determination Using the Endogenous OATP1B Marker Coproporphyrin and Tissue Gene Expression. Journal of Pharmacology and Experimental Therapeutics, 2020, 375, 139-151.	1.3	7
13	Absorption and Disposition of Coproporphyrin I (CPI) in Cynomolgus Monkeys and Mice: Pharmacokinetic Evidence to Support the Use of CPI to Inform the Potential for Organic Anion-Transporting Polypeptide Inhibition. Drug Metabolism and Disposition, 2020, 48, 724-734.	1.7	7
14	Renal Excretion of Dabigatran: The Potential Role of Multidrug and Toxin Extrusion (MATE) Proteins. Molecular Pharmaceutics, 2019, 16, 4065-4076.	2.3	10
15	Enhanced and Persistent Inhibition of Organic Cation Transporter 1 Activity by Preincubation of Cyclosporine A. Drug Metabolism and Disposition, 2019, 47, 1352-1360.	1.7	13
16	Dissecting the Contribution of OATP1B1 to Hepatic Uptake of Statins Using the OATP1B1 Selective Inhibitor Estropipate. Molecular Pharmaceutics, 2019, 16, 2342-2353.	2.3	27
17	Organic Anion Transporter Polypeptide 1B1 Polymorphism Modulates the Extent of Drugâ€“Drug Interaction and Associated Biomarker Levels in Healthy Volunteers. Clinical and Translational Science, 2019, 12, 388-399.	1.5	53
18	Xenobiotic Transporters in the Kidney: Function and Role in Toxicity. Seminars in Nephrology, 2019, 39, 159-175.	0.6	13

#	Article	IF	Citations
19	Evidence for the Validity of Pyridoxic Acid (PDA) as a Plasma-Based Endogenous Probe for OAT1 and OAT3 Function in Healthy Subjects. Journal of Pharmacology and Experimental Therapeutics, 2019, 368, 136-145.	1.3	38
20	Comprehensive Evaluation of the Utility of 20 Endogenous Molecules as Biomarkers of OATP1B Inhibition Compared with Rosuvastatin and Coproporphyrin I. Journal of Pharmacology and Experimental Therapeutics, 2019, 368, 125-135.	1.3	36
21	Discovery and Validation of Pyridoxic Acid and Homovanillic Acid as Novel Endogenous Plasma Biomarkers of Organic Anion Transporter (OAT) 1 and OAT3 in Cynomolgus Monkeys. Drug Metabolism and Disposition, 2018, 46, 178-188.	1.7	40
22	Gaining Mechanistic Insight Into Coproporphyrin I as Endogenous Biomarker for OATP1Bâ€Mediated Drugâ€“Drug Interactions Using Population Pharmacokinetic Modeling and Simulation. Clinical Pharmacology and Therapeutics, 2018, 104, 564-574.	2.3	56
23	In Vitro Stimulation of Multidrug Resistance-Associated Protein 2 Function Is Not Reproduced In Vivo in Rats. Pharmaceutics, 2018, 10, 125.	2.0	5
24	Clinical Probes and Endogenous Biomarkers as Substrates for Transporter Drugâ€Drug Interaction Evaluation: Perspectives From the International Transporter Consortium. Clinical Pharmacology and Therapeutics, 2018, 104, 836-864.	2.3	141
25	LCâ€“MS/MS bioanalysis of plasma 1, 14-tetradecanedioic acid and 1, 16-hexadecanedioic acid as candidate biomarkers for organic anion-transporting polypeptide mediated drugâ€“drug interactions. Bioanalysis, 2018, 10, 1473-1485.	0.6	5
26	Further Studies to Support the Use of Coproporphyrin I and III as Novel Clinical Biomarkers for Evaluating the Potential for Organic Anion Transporting Polypeptide 1B1 and OATP1B3 Inhibition. Drug Metabolism and Disposition, 2018, 46, 1075-1082.	1.7	44
27	UHPLCâ€“MS/MS bioanalysis of human plasma coproporphyrins as potential biomarkers for organic anion-transporting polypeptide-mediated drug interactions. Bioanalysis, 2018, 10, 633-644.	0.6	14
28	A pharmaceutical industry perspective on transporter and CYP-mediated drugâ€“drug interactions: kidney transporter biomarkers. Bioanalysis, 2018, 10, 625-631.	0.6	7
29	Tenofovir Disoproxil Fumarate Is Not an Inhibitor of Human Organic Cation Transporter 1. Journal of Pharmacology and Experimental Therapeutics, 2017, 360, 341-342.	1.3	6
30	Organic Anion Transporter 2: An Enigmatic Human Solute Carrier. Drug Metabolism and Disposition, 2017, 45, 228-236.	1.7	62
31	Physiologically Based Pharmacokinetic Modeling of Transporter-Mediated Hepatic Clearance and Liver Partitioning of OATP and OCT Substrates in Cynomolgus Monkeys. AAPS Journal, 2017, 19, 1878-1889.	2.2	13
32	Comparative Evaluation of Plasma Bile Acids, Dehydroepiandrosterone Sulfate, Hexadecanedioate, and Tetradecanedioate with Coproporphyrins I and III as Markers of OATP Inhibition in Healthy Subjects. Drug Metabolism and Disposition, 2017, 45, 908-919.	1.7	67
33	Endogenous Biomarkers to Assess Drug-Drug Interactions by Drug Transporters and Enzymes. Current Drug Metabolism, 2017, 18, 757-768.	0.7	29
34	Coproporphyrins I and III as Functional Markers of OATP1B Activity: In Vitro and In Vivo Evaluation in Preclinical Species. Journal of Pharmacology and Experimental Therapeutics, 2016, 357, 382-393.	1.3	88
35	Tissue distribution and tumor uptake of folate receptorâ€“targeted epothilone folate conjugate, BMS-753493, in CD2F1 mice after systemic administration. Acta Pharmaceutica Sinica B, 2016, 6, 460-467.	5.7	13
36	Coproporphyrins in Plasma and Urine Can Be Appropriate Clinical Biomarkers to Recapitulate Drug-Drug Interactions Mediated by Organic Anion Transporting Polypeptide Inhibition. Journal of Pharmacology and Experimental Therapeutics, 2016, 358, 397-404.	1.3	132

#	Article	IF	Citations
37	Cynomolgus Monkey as a Clinically Relevant Model to Study Transport Involving Renal Organic Cation Transporters: In Vitro and In Vivo Evaluation. Drug Metabolism and Disposition, 2016, 44, 238-249.	1.7	28
38	Characterization of Organic Anion Transporter 2 (SLC22A7): A Highly Efficient Transporter for Creatinine and Species-Dependent Renal Tubular Expression. Drug Metabolism and Disposition, 2015, 43, 984-993.	1.7	73
39	Evaluation of Rosuvastatin as an Organic Anion Transporting Polypeptide (OATP) Probe Substrate: In Vitro Transport and In Vivo Disposition in Cynomolgus Monkeys. Journal of Pharmacology and Experimental Therapeutics, 2015, 353, 380-391.	1.3	31
40	Rosuvastatin Liver Partitioning in Cynomolgus Monkeys: Measurement In Vivo and Prediction Using In Vitro Monkey Hepatocyte Uptake. Drug Metabolism and Disposition, 2015, 43, 1788-1794.	1.7	21
41	Triphenylethanamine Derivatives as Cholesteryl Ester Transfer Protein Inhibitors: Discovery of N-[(1R)-1-(3-Cyclopropoxy-4-fluorophenyl)-1-[3-fluoro-5-(1,1,2,2-tetrafluoroethoxy)phenyl]-2-phenylethyl]-4-fluoro-3-(tri (BMS-795311). Journal of Medicinal Chemistry, 2015, 58, 9010-9026.	2.9	11
42	Assessment of Vandetanib as an Inhibitor of Various Human Renal Transporters: Inhibition of Multidrug and Toxin Extrusion as a Possible Mechanism Leading to Decreased Cisplatin and Creatinine Clearance. Drug Metabolism and Disposition, 2013, 41, 2095-2103.	1.7	49
43	Cynomolgus Monkey as a Potential Model to Assess Drug Interactions Involving Hepatic Organic Anion Transporting Polypeptides: In Vitro, In Vivo, and In Vitro-to-In Vivo Extrapolation. Journal of Pharmacology and Experimental Therapeutics, 2013, 344, 673-685.	1.3	73